Prelude Therapeutics Newsroom

Morgan Stanley Maintains Prelude Therapeutics(PRLD.US) With Sell Rating

Moomoo NewsDec 12 05:31 ET · Ratings

Prelude Therapeutics (PRLD) Gets a Sell From Morgan Stanley

TipRanksDec 12 05:28 ET · Ratings

Prelude Therapeutics Analyst Ratings

BenzingaDec 11 12:22 ET · Ratings

Prelude Therapeutics Reports Promising Interim Data for PRT2527 in Relapsed/Refractory Lymphoid Malignancies, Plans Partnership for Future Development

Quiver QuantitativeDec 11 07:40 ET

Express News | Prelude Therapeutics Inc: Plans to Seek a Partner for Future Development of PRT2527 in Hematologic Malignancies

ReutersDec 11 07:31 ET

Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib in Patients With Relapsed/Refractory Lymphoid Malignancies

GlobeNewswireDec 11 07:30 ET

Express News | Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-Escalation Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib in Patients With Relapsed/Refractory Lymphoid Malignancies

ReutersDec 11 07:30 ET

JMP Securities Maintains Prelude Therapeutics(PRLD.US) With Buy Rating, Cuts Target Price to $4

Moomoo NewsDec 11 00:33 ET · Ratings

After Plunging -31.47% in 4 Weeks, Here's Why the Trend Might Reverse for Prelude Therapeutics (PRLD)

Zacks Nov 27 08:40 ET

Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit

GlobeNewswireNov 27 07:30 ET

Prelude Therapeutics Reports Progress in Clinical Trials and Financial Health

TipRanksNov 25 23:02 ET

Prelude Therapeutics Price Target Maintained With a $5.00/Share by HC Wainwright & Co.

Dow JonesNov 8 11:54 ET · Ratings

Prelude Therapeutics (PRLD) Receives a Sell From Barclays

TipRanksNov 8 04:51 ET · Ratings

Prelude Therapeutics: Promising Developments and Strategic Collaborations Drive Buy Rating

TipRanksNov 7 00:35 ET · Ratings

Prelude Therapeutics | 8-K: Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

SECNov 6 22:32 ET

Express News | Prelude Therapeutics Q3 EPS $(0.43) Beats $(0.47) Estimate

BenzingaNov 6 16:49 ET

Prelude Therapeutics | 10-Q: Q3 2024 Earnings Report

SECNov 6 16:32 ET · Announcements

Express News | Prelude Therapeutics Inc: Current Cash Runway Into 2026

ReutersNov 6 16:27 ET

Express News | Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

ReutersNov 6 16:05 ET

Press Release: Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Dow JonesNov 6 16:05 ET